Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026)
Halozyme Therapeutics (HALO) posted Raw Materials of $21.4 million for Q2 2026, up 20.3% from $17.79 million a year earlier but down 2.3% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) Raw Materials (2011 - 2026) Analysis & Trends
At the end of FY2025, Halozyme Therapeutics' Raw Materials came in at $21.87 million, down 8.9% from FY2024.
- Annual Raw Materials shows a five-year compound annual growth rate of 30.3% (FY2020 to FY2025).
- In prior years, Halozyme Therapeutics' Raw Materials was $24.02 million in FY2024 (+1.6%), $23.65 million in FY2023 (+71.4%), $13.79 million in FY2022 (+29.2%) and $10.67 million in FY2021 (+83.6%).
- Quarterly Raw Materials has run from a low of $8.11 million in Q3 2021 to a high of $30.58 million in Q3 2024 over five years.
- On a year-over-year basis, Raw Materials increased in four of the last eight quarters, with an average decline of 8.0%.
- The strongest year-over-year quarter for Raw Materials in the past five years was Q2 2023, with growth of 137.5%; the weakest was Q3 2025, with a decline of 38.0%.
- According to Business Quant data, Raw Materials for the three prior quarters was $21.9 million (Q1 2026), $21.87 million (Q4 2025) and $18.96 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn |
| 10 | Halozyme Therapeutics | 12.72 Bn | 11.33 Bn | 401.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.40 Mn |
| Mar 31, 2026 | 21.90 Mn |
| Dec 31, 2025 | 21.87 Mn |
| Sep 30, 2025 | 18.96 Mn |
| Jun 30, 2025 | 17.79 Mn |
| Mar 31, 2025 | 18.42 Mn |
| Dec 31, 2024 | 24.02 Mn |
| Sep 30, 2024 | 30.58 Mn |
| Jun 30, 2024 | 27.22 Mn |
| Mar 31, 2024 | 29.11 Mn |
| Dec 31, 2023 | 23.65 Mn |
| Sep 30, 2023 | 26.93 Mn |
| Jun 30, 2023 | 24.21 Mn |
| Mar 31, 2023 | 22.45 Mn |
| Dec 31, 2022 | 13.79 Mn |
| Sep 30, 2022 | 11.96 Mn |
| Jun 30, 2022 | 10.19 Mn |
| Mar 31, 2022 | 10.27 Mn |
| Dec 31, 2021 | 10.67 Mn |
| Sep 30, 2021 | 8.11 Mn |
API Access
Halozyme Therapeutics Raw Materials API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=raw-materials&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "raw-materials", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=raw-materials&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();